Key Takeaways
- • Armistice Capital's founder testified in federal court in California on April 21, 2026, defending the hedge fund against pump-and-dump allegations involving $250 million in Vaxart stock during the COVID-19 pandemic.
- • The defendant characterized the fund's gains as "lucky" and described the stock's rapid surge as "fun," framing the trading activity as fortunate market timing rather than coordinated manipulation.
- • The case centers on allegations of market manipulation during the pandemic period, when biotech and healthcare equities experienced significant volatility and retail investor interest.
Summary
Armistice Capital's founder took the witness stand in federal court on Tuesday, April 21, 2026, to defend his hedge fund against allegations of executing a pump-and-dump scheme involving Vaxart stock valued at approximately $250 million during the COVID-19 pandemic. According to Law360's reporting, the defendant characterized the fund's substantial gains in the stock as the result of favorable market conditions and timing rather than deliberate market manipulation.
In his testimony before a California federal jury, the Armistice Capital head described the experience of the stock's rapid appreciation as both "lucky" and "fun," suggesting that the fund's significant profits derived from advantageous positioning during a period of market volatility in biotech equities. This characterization represents a key strategic element of the defense, which appears to center on the argument that the fund's trading activity reflected market opportunity rather than coordinated schemes to artificially inflate the stock price and subsequently unload positions at inflated valuations.
The litigation reflects ongoing regulatory scrutiny of hedge fund trading practices during the pandemic period, when healthcare and biotechnology stocks experienced extraordinary volatility amid investor enthusiasm for vaccine-related equities and competing interpretations of regulatory catalysts. The case underscores the distinction between profitable market timing and potentially unlawful market manipulation schemes, a distinction that will be determined by the jury's evaluation of the evidence presented.
In his testimony before a California federal jury, the Armistice Capital head described the experience of the stock's rapid appreciation as both "lucky" and "fun," suggesting that the fund's significant profits derived from advantageous positioning during a period of market volatility in biotech equities. This characterization represents a key strategic element of the defense, which appears to center on the argument that the fund's trading activity reflected market opportunity rather than coordinated schemes to artificially inflate the stock price and subsequently unload positions at inflated valuations.
The litigation reflects ongoing regulatory scrutiny of hedge fund trading practices during the pandemic period, when healthcare and biotechnology stocks experienced extraordinary volatility amid investor enthusiasm for vaccine-related equities and competing interpretations of regulatory catalysts. The case underscores the distinction between profitable market timing and potentially unlawful market manipulation schemes, a distinction that will be determined by the jury's evaluation of the evidence presented.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.